Trevigen

Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 "High technology Corridor" in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, catalog, journal advertising, direct mail, and telemarketing. Distributor appointments have been made in North America, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.

Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. The previous decade saw a phenomenal increase in the number of investigators studying apoptosis, but only recently has the link between DNA damage and apoptosis received significant attention. We are pleased to continue to support the growing numbers of investigators moving into these overlapping fields of research. A logical extension of our focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation.

Trevigen Cell Assays, (TCA) a division of Trevigen, Inc, was established in 2008 to conduct contract research work for the pharmaceutical, biotechnology, government and academic segments of the research market. TCA specializes in designing and conducting assays for lead compound and genotoxic screening based on DNA damage and repair and cancer cell behavior.